119 related articles for article (PubMed ID: 24989481)
21. Structure-Based Virtual Screening for Ligands of G Protein-Coupled Receptors: What Can Molecular Docking Do for You?
Ballante F; Kooistra AJ; Kampen S; de Graaf C; Carlsson J
Pharmacol Rev; 2021 Oct; 73(4):527-565. PubMed ID: 34907092
[TBL] [Abstract][Full Text] [Related]
22. Urotensin II: a new pharmacologic target in the treatment of cardiovascular disease.
Desai N; Sajjad J; Frishman WH
Cardiol Rev; 2008; 16(3):142-53. PubMed ID: 18414185
[TBL] [Abstract][Full Text] [Related]
23. Urantide conformation and interaction with the urotensin-II receptor.
Brancaccio D; Limatola A; Campiglia P; Gomez-Monterrey I; Novellino E; Grieco P; Carotenuto A
Arch Pharm (Weinheim); 2014 Mar; 347(3):185-92. PubMed ID: 24357333
[TBL] [Abstract][Full Text] [Related]
24. Further insights into the pharmacology of the human trace amine-associated receptors: discovery of novel ligands for TAAR1 by a virtual screening approach.
Cichero E; Espinoza S; Franchini S; Guariento S; Brasili L; Gainetdinov RR; Fossa P
Chem Biol Drug Des; 2014 Dec; 84(6):712-20. PubMed ID: 24894156
[TBL] [Abstract][Full Text] [Related]
25. Virtual screen for ligands of orphan G protein-coupled receptors.
Bock JR; Gough DA
J Chem Inf Model; 2005; 45(5):1402-14. PubMed ID: 16180917
[TBL] [Abstract][Full Text] [Related]
26. Finding ligands for G protein-coupled receptors based on the protein-compound affinity matrix.
Fukunishi Y; Kubota S; Nakamura H
J Mol Graph Model; 2007 Jan; 25(5):633-43. PubMed ID: 16777448
[TBL] [Abstract][Full Text] [Related]
27. A novel urotensin II receptor antagonist, KR-36996, improved cardiac function and attenuated cardiac hypertrophy in experimental heart failure.
Oh KS; Lee JH; Yi KY; Lim CJ; Park BK; Seo HW; Lee BH
Eur J Pharmacol; 2017 Mar; 799():94-102. PubMed ID: 28163023
[TBL] [Abstract][Full Text] [Related]
28. Pharmacophore-based virtual screening, biological evaluation and binding mode analysis of a novel protease-activated receptor 2 antagonist.
Cho NC; Seo SH; Kim D; Shin JS; Ju J; Seong J; Seo SH; Lee I; Lee KT; Kim YK; No KT; Pae AN
J Comput Aided Mol Des; 2016 Aug; 30(8):625-37. PubMed ID: 27600555
[TBL] [Abstract][Full Text] [Related]
29. Pharmacophore generation, atom-based 3D-QSAR and molecular dynamics simulation analyses of pyridine-3-carboxamide-6-yl-urea analogues as potential gyrase B inhibitors.
Azam MA; Thathan J
SAR QSAR Environ Res; 2017 Apr; 28(4):275-296. PubMed ID: 28399673
[TBL] [Abstract][Full Text] [Related]
30. Characterization of Ligand Binding to GPCRs Through Computational Methods.
Vasile S; Esguerra M; Jespers W; Oliveira A; Sallander J; Åqvist J; Gutiérrez-de-Terán H
Methods Mol Biol; 2018; 1705():23-44. PubMed ID: 29188557
[TBL] [Abstract][Full Text] [Related]
31. Controlling the selectivity of aminergic GPCR ligands from the extracellular vestibule.
Egyed A; Kelemen ÁA; Vass M; Visegrády A; Thee SA; Wang Z; de Graaf C; Brea J; Loza MI; Leurs R; Keserű GM
Bioorg Chem; 2021 Jun; 111():104832. PubMed ID: 33826962
[TBL] [Abstract][Full Text] [Related]
32. Architecture of the human urotensin II receptor: comparison of the binding domains of peptide and non-peptide urotensin II agonists.
Lavecchia A; Cosconati S; Novellino E
J Med Chem; 2005 Apr; 48(7):2480-92. PubMed ID: 15801838
[TBL] [Abstract][Full Text] [Related]
33. From three-dimensional GPCR structure to rational ligand discovery.
Kooistra AJ; Leurs R; de Esch IJ; de Graaf C
Adv Exp Med Biol; 2014; 796():129-57. PubMed ID: 24158804
[TBL] [Abstract][Full Text] [Related]
34. Urotensin-II peptidomimetic incorporating a non-reducible 1,5-triazole disulfide bond reveals a pseudo-irreversible covalent binding mechanism to the urotensin G-protein coupled receptor.
Pacifico S; Kerckhoffs A; Fallow AJ; Foreman RE; Guerrini R; McDonald J; Lambert DG; Jamieson AG
Org Biomol Chem; 2017 May; 15(21):4704-4710. PubMed ID: 28524918
[TBL] [Abstract][Full Text] [Related]
35. From heptahelical bundle to hits from the Haystack: structure-based virtual screening for GPCR ligands.
Kooistra AJ; Roumen L; Leurs R; de Esch IJ; de Graaf C
Methods Enzymol; 2013; 522():279-336. PubMed ID: 23374191
[TBL] [Abstract][Full Text] [Related]
36. Predicted 3D structures for adenosine receptors bound to ligands: comparison to the crystal structure.
Goddard WA; Kim SK; Li Y; Trzaskowski B; Griffith AR; Abrol R
J Struct Biol; 2010 Apr; 170(1):10-20. PubMed ID: 20079848
[TBL] [Abstract][Full Text] [Related]
37. The impact of molecular dynamics sampling on the performance of virtual screening against GPCRs.
Tarcsay A; Paragi G; Vass M; Jójárt B; Bogár F; Keserű GM
J Chem Inf Model; 2013 Nov; 53(11):2990-9. PubMed ID: 24116387
[TBL] [Abstract][Full Text] [Related]
38. Mapping functional group free energy patterns at protein occluded sites: nuclear receptors and G-protein coupled receptors.
Lakkaraju SK; Yu W; Raman EP; Hershfeld AV; Fang L; Deshpande DA; MacKerell AD
J Chem Inf Model; 2015 Mar; 55(3):700-8. PubMed ID: 25692383
[TBL] [Abstract][Full Text] [Related]
39. Cardiorenovascular effects of urotensin II and the relevance of the UT receptor.
Tölle M; van der Giet M
Peptides; 2008 May; 29(5):743-63. PubMed ID: 17935830
[TBL] [Abstract][Full Text] [Related]
40. A virtual screen for diverse ligands: discovery of selective G protein-coupled receptor antagonists.
Engel S; Skoumbourdis AP; Childress J; Neumann S; Deschamps JR; Thomas CJ; Colson AO; Costanzi S; Gershengorn MC
J Am Chem Soc; 2008 Apr; 130(15):5115-23. PubMed ID: 18357984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
